Band Headlines Event for Fan with Lymphoma
Herald-Dispatch.com is reporting that TRIVIUM and LILITU are among the band that are teaming up to throw a 21st party birthday bash concert Friday, April 15, for Charleston, West Virginia resident Adam Weaver, who has been in an all-out war with Hodgkins Lymphoma cancer since he was diagnosed Oct. 8, 2002.
Like the heavy rock music he loves, Weaver has not let cancer take his spirit, and he is not going quietly.
Weaver, a big time fan of such bands as BLACK SABBATH and SLAYER, should be having a good time Friday, since he was already onto TRIVIUM, long before he found out they were coming in town to rock with him.
"It was kind of weird because none of my friends have been on to them like I have," Weaver said. "These guys are awesome, and I’m really thrilled they're playing at Ozzfest."
Read more at Herald-Dispatch.com.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
